WuXi Biologics (Cayman) Inc. (2269.HK)
| Previous close | 13.240 |
| Open | 13.120 |
| Bid | 12.560 x 0 |
| Ask | 12.560 x 0 |
| Day's range | 12.500 - 13.160 |
| 52-week range | 12.500 - 52.500 |
| Volume | |
| Avg. volume | 68,669,165 |
| Market cap | 52.344B |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 15.13 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
WuXi Biologics Reports Solid 2023 Annual Results
WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended December 31, 2023 ("Reporting Period").
- PR Newswire
WuXi Biologics Named to CDP 'A List' for Water Security
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for leadership in corporate transparency and performance on water security by the environmental non-profit CDP, securing a place on its annual 'A List'.
- PR Newswire
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in the 2023 Climate Change Assessment conducted by the global environmental non-profit CDP, achieving the Leadership level with a score of "A-".
